Allogene Therapeutics (ALLO) Free Cash Flow (2018 - 2026)
Allogene Therapeutics (ALLO) free cash flow from Mar 31, 2018 to Mar 31, 2026. The TTM Allogene Therapeutics (ALLO) free cash flow is -$110M. You can adjust inflation or export chart.
All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.
Annual Free Cash Flow
Quarterly Free Cash Flow
Allogene Therapeutics (ALLO) Free Cash Flow CAGR table
| Period | CAGR |
|---|---|
| 1 Year TTM | -44.72% |
| 3 Years TTM | -21.13% |
| 5 Years TTM | -9.83% |
| All Time TTM | +4.22% |
Annual Free Cash Flow change of Allogene Therapeutics (ALLO)
| Year | Free Cash Flow | Change |
|---|---|---|
| 2026 | -$13M | -91.37% |
| 2025 | -$150M | -25.55% |
| 2024 | -$201M | -15.99% |
| 2023 | -$239M | +6.00% |
| 2022 | -$226M | +9.43% |
| 2021 | -$206M | +13.92% |
| 2020 | -$181M | -3.77% |
| 2019 | -$188M | +292.94% |
| 2018 | -$48M | N/A |
Comparison Allogene Therapeutics (ALLO) five years free cash flow CAGR with competitors
Allogene Therapeutics (ALLO) five years free cash flow CAGR is -9.83%.